Subscribe

News
Media
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

The Benefits of GLP-1 Agonists for Type 2 Diabetes

EP. 1: Rationale for GLP-1 Therapy in T2D

March 1st 2019

EP. 2: T2D Treatment Guidelines: GLP-1 Agonists

March 1st 2019

EP. 3: Awareness of GLP-1 Therapy in T2D

March 1st 2019

EP. 4: Initiating Therapy With a GLP-1 Agonist in T2D

March 1st 2019

EP. 5: GLP-1 Therapy in T2D: Counseling Patients

March 1st 2019

EP. 6: Monitoring Patients on GLP-1 Therapy for T2D

March 1st 2019

EP. 7: Selecting and Using a GLP-1 Agonist in T2D

March 1st 2019

EP. 8: Current GLP-1 Agonists for the Treatment of T2D

March 1st 2019

EP. 9: GLP-1 Agonists in T2D: Response to Therapy

March 1st 2019

EP. 10: Managing T2D Patients on GLP-1 Therapy

March 1st 2019

EP. 11: GLP-1 Agonists in T2D: Role of the Community Pharmacist

March 1st 2019

EP. 12: Members of the Diabetes Care Team, Explored

March 1st 2019

EP. 13: Certified Diabetes Educator: A Resource for Patients

March 1st 2019

EP. 14: Navigating Patients Through T2D Therapy in the Pharmacy

March 1st 2019

EP. 15: Exciting Therapies and Technologies in T2D

March 1st 2019

Trending on Pharmacy Times

Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy

Fall 2025 Quiz: Test Your Pharmacy Knowledge!

FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms

New Data Show Elinzanetant Is a Safe, Well-Tolerated Non-Hormonal Therapy for Menopausal Vasomotor Symptoms

High Non-HDL-C/HDL-C Ratio in Adults With Obesity Increases Depression Risk

© 2025 MJH Life Sciences^®

All rights reserved.